Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00820950 · ClinicalTrials.gov registry record · Phase 2
A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT00820950 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 29 participants.
The verdict
NCT00820950, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
The study is comprised of two parts. The first portion of this study will be a double-blind, Sponsor-unblinded, vehicle-controlled study with application of ruxolitinib or vehicle to paired lesions at least 15 cm apart in patients with active but stable plaque psoriasis. Part 2 of the study is a double-blind, sponsor unblinded, comparison of ruxolitinib with two FDA approved products in patients with active but stable plaque psoriasis.
Interventions
- DRUG Placebo cream
- DRUG Ruxolitinib phosphate cream
- DRUG Dovonex® calcipotriene 0.005%
- DRUG Diprolene® AF betamethasone dipropionate 0.05% cream.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2007-05-31 |
| Est. Completion | 2009-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00820950
The ClinicalTrials.gov registry entry for NCT00820950 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo cream is the first listed.
NCT00820950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00820950 about?
NCT00820950 is a clinical study titled "A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis". The study is comprised of two parts. The first portion of this study will be a double-blind, Sponsor-unblinded, vehicle-controlled study with application of ruxolitinib or vehicle to paired lesions at least 15 cm apart in patients with active but stable plaque psoriasis. Part 2 of the study is a dou...
What is the current status of trial NCT00820950?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2007-05-31. Estimated completion is 2009-04-30.
What interventions are being tested in trial NCT00820950?
The interventions under investigation include: Placebo cream (DRUG), Ruxolitinib phosphate cream (DRUG), Dovonex® calcipotriene 0.005% (DRUG), Diprolene® AF betamethasone dipropionate 0.05% cream. (DRUG).
Who is sponsoring clinical trial NCT00820950?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.